Compare Quest Diagnostics Inc (DGX) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs MakeMyTrip Ltd — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while MakeMyTrip Ltd trades at $44.73 (market cap $4.09B). The key difference: Quest Diagnostics Inc is far larger — about 6.2× MakeMyTrip Ltd's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and MakeMyTrip Ltd for 12 Days on average.
| DGX | MMYT | |
|---|---|---|
Market Cap | $25.48B | $4.09B |
Volume | 941,866 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $247.45 | $94.43 |
52-Week Low | $173.49 | $36.30 |
Typical Hold Time | 56 Days | 12 Days |
Enterprise Value | $31.23B | $4.75B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
MakeMyTrip (MMYT) trades at $43.53, up 0.28% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported mixed quarterly earnings, with a Q1 2026 beat and Q4 2025 and Q2 2026 misses. Revenue grew to $978.34M in 2025, but net income margin compressed to 3.23% in 2026. Analyst consensus is strongly bullish with a $77.00 price target, though institutional selling has been noted recently.
The outlook is bifurcated: strong analyst support and a potential Indian listing offer upside, but declining profitability, high P/E ratio, and bearish technicals pose risks. Investors face volatility from operational execution and travel industry cyclicality against a backdrop of Wall Street optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
